股本结构
单位：万股
| 公告日期 | 2024-03-14 | 2024-03-14 | 2023-12-15 | 2023-12-15 | 2023-12-15 | 2023-03-16 |
|---|---|---|---|---|---|---|
| 证券总股本 | 9889.89 | 9919.78 | 9880.14 | 8450.14 | 8444.94 | 8974.54 |
| 普通股本 | 9889.89 | 9919.78 | 9880.14 | 8450.14 | 8444.94 | 8974.54 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-14 | 2023-12-31 | 2023-12-19 | 2023-12-15 | 2023-09-30 | 2023-03-16 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-14 | 9889.89 | 未披露 | 定期报告 | 2024-03-14 |
| 2024-03-14 | 9919.78 | 未披露 |
更多>>
From January 1, 2023 to December 31,2023
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs
Proceeds from public offerings, net of underwriting fees, transaction costs and stamp duty
Restricted share awards
Exercise of options
|
2023-12-31 |
| 2023-12-15 | 9880.14 | 未披露 |
更多>>
Common stock offered 14,300,000 shares by the company
|
2023-12-19 |
| 2023-12-15 | 8450.14 | 未披露 | 定期报告 | 2023-12-15 |
| 2023-12-15 | 8444.94 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-03-16 | 8974.54 | 未披露 | 定期报告 | 2023-03-16 |
| 2023-03-16 | 8362.04 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of shares – incentive plans, net of transaction costs
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs
|
2022-12-31 |
| 2022-05-19 | 8355.23 | 未披露 | 定期报告 | 2022-05-19 |
| 2022-03-22 | 8347.90 | 未披露 |
更多>>
From January 1, 2021 to December 31, 2021
IPR&D asset purchase
Asset acquisition – common shares
Conversion note agreements
Held as treasury shares
Restricted share awards
Exercise of options
|
2021-12-31 |
| 2021-05-05 | 7265.24 | 未披露 | 定期报告 | 2021-05-05 |
| 2021-05-05 | 7265.27 | 未披露 | 定期报告 | 2021-03-31 |
| 2021-04-28 | 7265.24 | 未披露 | 定期报告 | 2021-03-22 |
| 2021-03-23 | 7270.17 | 未披露 | 定期报告 | 2021-03-01 |
| 2021-03-23 | 7193.67 | 未披露 |
更多>>
from January 1, 2020 to December 31, 2020
Issuance of shares:
Held as treasury shares, net of transaction costs
Exercise of options
|
2020-12-31 |
| 2020-09-08 | 7174.13 | 未披露 | 定期报告 | 2020-06-30 |
| 2020-03-30 | 7185.94 | 未披露 |
更多>>
From January 1, 2019 to December 31, 2019
Conversion of note agreement, net of transaction costs
Restricted Share Awards
Exercise of options
|
2019-12-31 |
| 2019-03-21 | 6756.23 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of Shares – Incentive Plans
Issuance of Shares – Public Offering (net of transaction costs)
|
2018-12-31 |
| 2018-08-24 | 6736.27 | 未披露 | 定期报告 | 2018-08-24 |
| 2018-08-24 | 6745.23 | 未披露 | 定期报告 | 2018-08-22 |
| 2018-07-23 | 6586.27 | 未披露 |
更多>>
On July 18, 2018, AC Immune SA (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC and UBS Securities LLC (the “Underwriters”), relating to the issuance and sale (the “Offering”) of 7,391,305 of the Company’s common shares (“Common Shares”), nominal value CHF 0.02 per share. On July 19, 2018, the Underwriters exercised their 30-day option to purchase an additional 1,108,695 Common Shares in full, resulting in approximately $12.2 million of additional proceeds to the Company, after deducting underwriting discounts and other estimated offering expenses.
|
2018-07-23 |
| 2018-05-25 | 5740.06 | 未披露 | 定期报告 | 2018-05-22 |
| 2018-05-04 | 5739.43 | 未披露 | 定期报告 | 2018-05-01 |
| 2018-07-17 | 5736.27 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-20 | 5735.52 | 未披露 | 定期报告 | 2017-12-31 |
| 2017-03-17 | 5692.22 | 未披露 | 定期报告 | 2017-03-01 |
| 2017-03-17 | 5677.34 | 未披露 | 定期报告 | 2016-12-31 |
| 2016-09-23 | 5539.60 | 未披露 | 定期报告 | 2016-09-23 |
| 2016-09-13 | 4939.60 | 未披露 | 定期报告 | 2016-08-31 |
| 2016-09-07 | 1081.90 | 3857.70 | 定期报告 | 2016-06-30 |
| 2016-07-11 | 4858.00 | 未披露 | 定期报告 | 2016-06-06 |
| 2016-05-31 | 922.73 | 3717.53 | 定期报告 | 2016-03-31 |
From January 1, 2023 to December 31,2023
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs
Proceeds from public offerings, net of underwriting fees, transaction costs and stamp duty
Restricted share awards
Exercise of options
Common stock offered 14,300,000 shares by the company
From December 31, 2021 to December 31, 2022
Issuance of shares – incentive plans, net of transaction costs
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs
From January 1, 2021 to December 31, 2021
IPR&D asset purchase
Asset acquisition – common shares
Conversion note agreements
Held as treasury shares
Restricted share awards
Exercise of options
from January 1, 2020 to December 31, 2020
Issuance of shares:
Held as treasury shares, net of transaction costs
Exercise of options
From January 1, 2019 to December 31, 2019
Conversion of note agreement, net of transaction costs
Restricted Share Awards
Exercise of options
from December 31, 2017 to December 31, 2018
Issuance of Shares – Incentive Plans
Issuance of Shares – Public Offering (net of transaction costs)
On July 18, 2018, AC Immune SA (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC and UBS Securities LLC (the “Underwriters”), relating to the issuance and sale (the “Offering”) of 7,391,305 of the Company’s common shares (“Common Shares”), nominal value CHF 0.02 per share. On July 19, 2018, the Underwriters exercised their 30-day option to purchase an additional 1,108,695 Common Shares in full, resulting in approximately $12.2 million of additional proceeds to the Company, after deducting underwriting discounts and other estimated offering expenses.